Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CONTRAFECT CorpCFRX · Entity 116797 | SVP Business Development | February 01, 2018 | February 07, 2018 |
| Cardiff Oncology, Inc.CRDF · Entity 6917 | Chief Financial Officer | April 06, 2026 | April 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CONTRAFECT Corp
Report date February 01, 2018 · Filed February 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.44 · Expires 2028-02-01 | Direct | 200,000 |
Reported balance
Holding disclosure · report date 2018-02-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance 200,000 F1: Grant award made under the ContraFect Corporation Omnibus Incentive Plan. Grant vests over four years, 6.25% at the end of each quarter following the vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant award made under the ContraFect Corporation Omnibus Incentive Plan. Grant vests over four years, 6.25% at the end of each quarter following the vesting commencement date.
Cardiff Oncology, Inc.
Report date April 06, 2026 · Filed April 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 500 |
Reported balance
Holding disclosure · report date 2026-04-06 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 500 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 06, 2026 Filed Apr 17, 2026 00:07 UTC Amendment | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 486,650 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001651911-26-000006 · ownership.xml · derivative · entry 1 Muntner Joshua B · CIK 0001651911 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 487,150 Underlying: Common Stock · 486,650 shares Expires 2036-04-06 F1 · derivative.exercise_date: 121,663 vest on April 6, 2027 and 10,139 vest monthly for 36 months thereafter. Read SEC document |
| April 06, 2026 Filed Apr 16, 2026 20:01 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 486,650 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001651911-26-000004 · ownership.xml · derivative · entry 2 Muntner Joshua B · CIK 0001651911 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 487,150 Underlying: Common Stock · 486,650 shares Expires 2036-04-06 F1 · derivative.exercise_date: 121,663 vest on April 6, 2027 and 10,139 vest monthly for 36 months thereafter. Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 16:52 UTC | CONTRAFECT Corp CFRX · Entity 116797 | PurchaseWarrants (Right to Buy) · Derivative | 1,000 | $0.01 Strike: $1.55 | $10.00 |
DisclosureSEC source: 0001209191-17-046333 · doc4.xml · derivative · entry 2 Muntner Joshua B · CIK 0001651911 · SVP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock, par value $0.0001 per share · 1,000 shares Expires 2022-07-25 Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 16:52 UTC | CONTRAFECT Corp CFRX · Entity 116797 | PurchaseCommon Stock, par value $0.0001 per share | 2,000 | $1.24 | $2,480.00 |
DisclosureSEC source: 0001209191-17-046333 · doc4.xml · nonDerivative · entry 1 Muntner Joshua B · CIK 0001651911 · SVP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.